Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Personalis, Inc. - Common Stock (NQ:PSNL)

12.86 -0.58 (-4.32%)
Streaming Delayed Price Updated: 3:25 PM EDT, Jul 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,596,673
Open 13.34
Bid (Size) 12.85 (700)
Ask (Size) 12.87 (200)
Prev. Close 13.44
Today's Range 12.84 - 13.41
52wk Range 3.840 - 16.39
Shares Outstanding 48,518,901
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Halper Sadeh LLC is Investigating Whether UTZ, PSNL, LXP are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL
From Kahn Swick & Foti, LLC
Via Business Wire

Performance

YTD
+63.8%
+63.8%
1 Month
+26.5%
+26.5%
3 Month
+106.1%
+106.1%
6 Month
+37.0%
+37.0%
1 Year
+107.4%
+107.4%

More News

Read More
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)
From Brodsky & Smith LLC
Via GlobeNewswire
Personalis (NASDAQ:PSNL) Volume Surge Can't Mask Q1 Miss as Losses Widen ↗
Via Chartmill
News headline image
PSNL Stock Alert: Halper Sadeh LLC is Investigating Whether Personalis, Inc. is Obtaining a Fair Price for Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
From Personalis, Inc.
Via Business Wire
News headline image
Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate in Upcoming Investor Events
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Personalis (PSNL) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Personalis Reports First Quarter Results and Recent Highlights
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Announce First Quarter 2026 Financial Results
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026
From Personalis, Inc.
Via Business Wire
News headline image
Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate in the 25th Annual Needham Virtual Conference
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®
From Personalis, Inc.
Via Business Wire
News headline image
Lightspeed Makes a Big Bet on Self-Driving Trucks, Loading Up on 7 Million Shares of Kodiak AI (KDK) ↗
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
Lightspeed Management Made a Huge Bet on Navan (NAVN) With a Purchase of 49.9 Million Shares ↗
Via The Motley Fool
Topics Regulatory Compliance

Frequently Asked Questions

Is Personalis, Inc. - Common Stock publicly traded?
Yes, Personalis, Inc. - Common Stock is publicly traded.
What exchange does Personalis, Inc. - Common Stock trade on?
Personalis, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Personalis, Inc. - Common Stock?
The ticker symbol for Personalis, Inc. - Common Stock is PSNL on the Nasdaq Stock Market
What is the current price of Personalis, Inc. - Common Stock?
The current price of Personalis, Inc. - Common Stock is 12.86
When was Personalis, Inc. - Common Stock last traded?
The last trade of Personalis, Inc. - Common Stock was at 07/22/26 03:25 PM ET
What is the market capitalization of Personalis, Inc. - Common Stock?
The market capitalization of Personalis, Inc. - Common Stock is 623.95M
How many shares of Personalis, Inc. - Common Stock are outstanding?
Personalis, Inc. - Common Stock has 624M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.